Videos
Winston Tan, MD, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors, namely agents like avapritinib and ripretinib, which have shown promise in ongoing clinical trials.<br />
Ethan Basch, MD, MSc, recently received the Clinical Research Award from the Association of Community Cancer Centers during the 2019 National Oncology Conference. Basch explains the importance of receiving this award in light of his work around patient-reported outcomes for symptom monitoring in oncology.
Ali McBride, PharmD, MS, BCOP, discussed during the recent National Oncology Conference his goals for ACCC while serving as president, which include focusing on education, innovation, and compensation.<br />
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.<br />
Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti–PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br />
Kerry Rogers, MD, discusses the rationale for evaluating ibrutinib in patients with hairy cell leukemia in the phase II trial.
Fred R. Hirsch, MD, PhD, discusses how genomic testing has expanded over the last few years and has impacted the lung cancer treatment paradigm.